FindTrial
Sign In

The Study of 68Ga-PSMA PET/MR Multimodal Imaging in the Differential Diagnosis of Postoperative Recurrence and Pseudoprogression of High grade Glioma

The Study of 68Ga-PSMA PET/MR Multimodal Imaging in the Differential Diagnosis of Postoperative Recurrence and Pseudoprogression of High grade Glioma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076481
Enrollment
Unknown
Registered
2023-10-10
Start date
2023-10-31
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-grade gliomas

Interventions

Gold Standard:Pathological biopsy
Index test:68Ga-PSMA PET/MR imaging

Sponsors

Xijing hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) All patients underwent surgical resection and were pathologically diagnosed as III-IV glioma patients after surgery; 2) Postoperative routine radiotherapy; 3) After surgery and radiation therapy, routine MRI follow-up was performed, with 2 or more follow-up visits showing new abnormal enhancement lesions; 4) Plan to undergo secondary surgical treatment, obtain surgical specimens and pathology

Exclusion criteria

Exclusion criteria: 1) MRI after surgery and before radiotherapy indicates clear enhancement lesions; 2) Those who merge with other malignant tumors and have brain metastasis; 3) Individuals with contraindications to PET/MR examination

Design outcomes

Primary

MeasureTime frame
SUV;Histopathology;ASL-CBV blood flow perfusion (rCBV);Accuracy ;Sensitivity ;Specificity ;—

Countries

China

Contacts

Public ContactFei Kang

Xijing hospital

fmmukf@qq.com+86 29 8477 5584

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026